BI,Lilly扩展Jardiance在心脏衰竭的应用

2018-03-07 MedSci MedSci原创

勃林格殷格翰(Boehringer Ingelheim)和礼来(Eli Lilly)正在扩大他们的临床试验计划,以促进慢性心力衰竭(CHF)的临床试验,并进行两项新的三期研究。Emperial临床试验计划将评估12周的治疗对CHF患者的运动能力和心力衰竭症状的影响,与他们是否患有II型糖尿病无关。这一举措是在去年启动了EMPEROR试验之后开展的,该试验侧重于心力衰竭患者的长期发病率和死亡率结果,

勃林格殷格翰(Boehringer Ingelheim)和礼来(Eli Lilly)正在扩大他们的临床试验计划,以促进慢性心力衰竭(CHF)的临床试验,并进行两项新的三期研究。Emperial临床试验计划将评估12周的治疗对CHF患者的运动能力和心力衰竭症状的影响,与他们是否患有II型糖尿病无关。这一举措是在去年启动了EMPEROR试验之后开展的,该试验侧重于心力衰竭患者的长期发病率和死亡率结果,以及来自具有里程碑意义的EMPA-REG OUTCOME试验的数据,该试验显示该药可降低心血管风险 II型糖尿病成人死亡,并建立了心血管疾病,在研究开始时与血糖控制无关。当Jardiance被添加到常见的一线和二线糖尿病药物如二甲双胍或磺酰脲类药物中时,心血管死亡率也有所下降。"我们对Jardiance在EMPA-REG OUTCOME试验中发现的心脏衰竭结果感到鼓舞,并期待来自我们正在进行的其他试验的额外数据,"勃林格殷格翰初级保健临床开发和医疗事务副总裁Thomas Seck指出。心力衰竭影响全球2600万人,并伴有高发病率和死亡率。"心力衰竭的症状会对生活质量产生深远的影响,超过四分之三

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638473, encodeId=1b4b16384e3f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 26 09:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028053, encodeId=0c4d202805390, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Sun Aug 26 19:27:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438711, encodeId=fde21438e11f4, content=<a href='/topic/show?id=5c6b516e1dd' target=_blank style='color:#2F92EE;'>#心脏衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51671, encryptionId=5c6b516e1dd, topicName=心脏衰竭)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585513, encodeId=e5a6158551308, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293930, encodeId=429c29393080, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Mar 07 20:36:54 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638473, encodeId=1b4b16384e3f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 26 09:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028053, encodeId=0c4d202805390, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Sun Aug 26 19:27:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438711, encodeId=fde21438e11f4, content=<a href='/topic/show?id=5c6b516e1dd' target=_blank style='color:#2F92EE;'>#心脏衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51671, encryptionId=5c6b516e1dd, topicName=心脏衰竭)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585513, encodeId=e5a6158551308, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293930, encodeId=429c29393080, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Mar 07 20:36:54 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
    2018-08-26 syscxl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638473, encodeId=1b4b16384e3f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 26 09:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028053, encodeId=0c4d202805390, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Sun Aug 26 19:27:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438711, encodeId=fde21438e11f4, content=<a href='/topic/show?id=5c6b516e1dd' target=_blank style='color:#2F92EE;'>#心脏衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51671, encryptionId=5c6b516e1dd, topicName=心脏衰竭)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585513, encodeId=e5a6158551308, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293930, encodeId=429c29393080, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Mar 07 20:36:54 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638473, encodeId=1b4b16384e3f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 26 09:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028053, encodeId=0c4d202805390, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Sun Aug 26 19:27:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438711, encodeId=fde21438e11f4, content=<a href='/topic/show?id=5c6b516e1dd' target=_blank style='color:#2F92EE;'>#心脏衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51671, encryptionId=5c6b516e1dd, topicName=心脏衰竭)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585513, encodeId=e5a6158551308, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293930, encodeId=429c29393080, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Mar 07 20:36:54 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
    2018-03-09 lq1773
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638473, encodeId=1b4b16384e3f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 26 09:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028053, encodeId=0c4d202805390, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10890, encryptionId=a3141089068, topicName=Lilly)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Sun Aug 26 19:27:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438711, encodeId=fde21438e11f4, content=<a href='/topic/show?id=5c6b516e1dd' target=_blank style='color:#2F92EE;'>#心脏衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51671, encryptionId=5c6b516e1dd, topicName=心脏衰竭)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585513, encodeId=e5a6158551308, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Fri Mar 09 11:27:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293930, encodeId=429c29393080, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Mar 07 20:36:54 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
    2018-03-07 changjiu

    学习一下谢谢

    0

相关资讯

ADA 2016:恩格列净能减缓2型糖尿病患者的肾病进展

美国糖尿病协会科学年会上公布了EMPA-REG OUTCOME最新研究数据,与安慰剂相比,SGLT2抑制剂恩格列净能减缓肾脏疾病进展、减少临床相关的肾脏事件。德国的研究人员Christoph Wanner说,约35%的2型糖尿病人群伴有肾脏疾病。EMPA-REG OUTCOME研究的主要目的是评估恩格列净的心血管结局。研究人员发现,有心血管(CV)病史的2型糖尿病成年患者其CV死亡率和全因死亡率显

降糖药Jardiance缓解肾功能障碍

今天礼来和BI宣布其二型糖尿病药物,SGLT2抑制剂Jardiance除了显示心血管收益外,还缓解肾功能障碍。这是那个名为EMPA-REG前瞻性临床试验的次级终点。这个有7000多人参与四期临床试验的一级终点是心血管事件,平均跟踪3.1年显示和标准疗法联用Jardiance比安慰剂能降低心梗、心脏病死亡、和中风发病风险。今天在ADA公布并在NEJM发表的是这个实验次级终点。和标准疗法联用Jardi

本周糖尿病重磅:强生降糖药INVOKAMET获FDA批准一线治疗2型糖尿病,英国NICE推荐3种SGLT-2降糖药

英国医疗成本监管机构NICE(英国国家卫生与临床优化研究所)近日发布指南,推荐3种糖尿病单药疗法用于英格兰和威尔士国家卫生服务(NHS)系统,用于2型糖尿病患者的治疗,包括强生的Invokana(canagliflozin,卡格列净)、阿斯利康的Forxiga(dapagliflozin,达格列净)、勃林格殷格翰的Jardiance(empagliflozin,恩格列净)。 目前,在全球范围内,

重磅!勃林格-礼来降糖药Jardiance在确诊心血管疾病的2型糖尿病患者中显著延缓肾病进展风险

勃林格殷格翰-礼来糖尿病联盟近日在美国新奥尔良举行的2016年第76届美国糖尿病协会(ADA)科学会议(2016年06月10日-14日)上公布了糖尿病药物Jardiance(empagliflozin,恩格列净)里程碑意义的临床研究(EMPA-REG OUTCOME)新的分析数据。数据显示,在确诊心血管(CV)疾病的2型糖尿病成人患者中,与安慰剂+标准护理(包括降糖药和CV药物)相比,Jard